BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

With its latest $450 million fund, Venrock has eschewed the broader industry trend toward raising record funds, preferring to maintain a modest slate of early-stage investments in first-in-class therapies, genomics platforms and healthcare IT.  According...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

The founders of VastBiome have parlayed a Texas Medical Center Biodesign fellowship into support from the Illumina Accelerator, and now a $4.5 million seed round co-led by Merck Global Health Innovation Fund. Launched in Houston...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

LifeEDIT debuted with undisclosed funding from ElevateBio and former parent company AgBiome this week to develop novel RNA-guided nucleases and base editors that could offer broader genome access than...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

Flagship’s latest portfolio company mash-up brings together technologies that take advantage of microbial and plant biology to treat human disease. Senda Biosciences rolls together four companies founded...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut. The biotech, which emerged...
BioCentury | Oct 3, 2020
Emerging Company Profile

OriCiro: replacing conventional bacterial cloning

OriCiro aims to provide plasmid DNA manufacturing to pharmas using a cell-free method of in vitro genome propagation that could be safer and faster than conventional Escherichia coli cloning....
BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets.  Hexagon Bio Inc. announced...
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds....
Items per page:
1 - 10 of 433
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

With its latest $450 million fund, Venrock has eschewed the broader industry trend toward raising record funds, preferring to maintain a modest slate of early-stage investments in first-in-class therapies, genomics platforms and healthcare IT.  According...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

The founders of VastBiome have parlayed a Texas Medical Center Biodesign fellowship into support from the Illumina Accelerator, and now a $4.5 million seed round co-led by Merck Global Health Innovation Fund. Launched in Houston...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

LifeEDIT debuted with undisclosed funding from ElevateBio and former parent company AgBiome this week to develop novel RNA-guided nucleases and base editors that could offer broader genome access than...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

Flagship’s latest portfolio company mash-up brings together technologies that take advantage of microbial and plant biology to treat human disease. Senda Biosciences rolls together four companies founded...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut. The biotech, which emerged...
BioCentury | Oct 3, 2020
Emerging Company Profile

OriCiro: replacing conventional bacterial cloning

OriCiro aims to provide plasmid DNA manufacturing to pharmas using a cell-free method of in vitro genome propagation that could be safer and faster than conventional Escherichia coli cloning....
BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets.  Hexagon Bio Inc. announced...
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds....
Items per page:
1 - 10 of 433